Compare ACB & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACB | RCKT |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.3M | 239.3M |
| IPO Year | 2016 | 2014 |
| Metric | ACB | RCKT |
|---|---|---|
| Price | $4.07 | $2.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $4.29 | ★ $8.58 |
| AVG Volume (30 Days) | 986.4K | ★ 2.1M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.38 | $915.60 |
| P/E Ratio | ★ N/A | $3.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.56 | $2.17 |
| 52 Week High | $6.36 | $5.45 |
| Indicator | ACB | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 45.08 |
| Support Level | $3.75 | $2.17 |
| Resistance Level | $4.15 | $2.78 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 43.00 | 53.47 |
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.